Poor
Not Aligned
Patient Risk:
High
Summary
Several safety/side-effect and indication statements are unsupported or inaccurate relative to the provided label excerpts; the response lacks required label specifics (e.g., risk-based indications and dosing context) and includes multiple side effects not supported as “common” for Lipitor in the provided label sections.
Category Scores
Accurate Statements
Rarer cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and with other drugs in this class.
Section 5.1 — “Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR…”
Liver enzyme abnormalities (transaminase elevations) are discussed in warnings/precautions and are a serious adverse reaction area in the label.
Section 5.2 — “Persistent elevations … in serum transaminases occurred…” and Section 6 — “The following serious adverse reactions are discussed… Liver enzyme abnormalities [5.2].”
Unsupported Statements
Lipitor (atorvastatin) is used to prevent heart disease.
The provided indication excerpt specifies therapy as adjunct to diet for hypercholesterolemia/risk-factor populations and includes a trial section on prevention of cardiovascular disease, but the response does not align to the label’s indication language provided in Section 1; “prevent heart disease” is not directly supported by the supplied Section 1 wording.
The most common side effects of Lipitor include muscle pain or weakness (rhabdomyolysis).
Label lists common adverse reactions leading to discontinuation (e.g., myalgia, diarrhea, nausea, ALT increase, hepatic enzyme increase) and “most commonly reported” reactions, but does not characterize rhabdomyolysis as a most-common side effect; rhabdomyolysis is described as rare in Section 5.1.
Headache is a common side effect of Lipitor.
Headache is not listed among the “most commonly reported adverse reactions” in Section 6.1 excerpts provided.
Fatigue is a common side effect of Lipitor.
Fatigue is not listed among the “most commonly reported adverse reactions” in Section 6.1 excerpts provided.
Sore throat is a common side effect of Lipitor.
No label excerpt provided lists sore throat as common; nasopharyngitis is listed as common but is not the same as “sore throat.”
Nausea or vomiting is a common side effect of Lipitor.
Section 6.1 provided includes nausea (0.4%) as one of the adverse reactions leading to discontinuation, but the response claims nausea/vomiting as “common side effects” broadly; label “most commonly reported” list does not include nausea/vomiting.
Diarrhea or abdominal pain is a common side effect of Lipitor.
Diarrhea appears in the label as both a discontinuation adverse reaction (0.5%) and most commonly reported (6.8%), but “abdominal pain” is not separately listed in the provided excerpts as a common adverse reaction.
Dizziness or lightheadedness is a common side effect of Lipitor.
Not listed among the “most commonly reported adverse reactions” in the provided Section 6.1 excerpts.
Cold or flu symptoms are a common side effect of Lipitor.
Not supported as such in the provided Section 6.1 excerpts.
Cough or sore lips is a common side effect of Lipitor.
Not listed among the “most commonly reported adverse reactions” in the provided Section 6.1 excerpts.
Rarer but more serious side effects of Lipitor include pancreatitis (inflammation of the pancreas).
Pancreatitis is not listed in the provided label sections/excerpts as a serious adverse reaction.
Rarer but more serious side effects of Lipitor include allergic reactions (such as anaphylaxis).
No allergy/anaphylaxis serious adverse reaction is included in the provided label excerpts.
Rarer but more serious side effects of Lipitor include blood sugar changes (hypoglycemia or hyperglycemia).
No blood sugar adverse reaction information is included in the provided label excerpts.
Rarer but more serious side effects of Lipitor include immune system disorders (such as lupus or vasculitis).
No lupus/vasculitis or immune system disorder adverse reaction is included in the provided label excerpts.
The Lipitor label has been updated to reflect concerns about muscle damage and liver injury.
The provided label excerpts do not state any label update history; the claim is not supported by the supplied text.
Clinical trial data and post-marketing reports have identified rare cases of rhabdomyolysis and liver enzyme elevation.
The provided excerpts support rarity of rhabdomyolysis (Section 5.1) and transaminase elevations (Section 5.2, and seriousness discussion in Section 6), but do not mention “post-marketing reports.”
Lipitor's patent expired in 2011, allowing generic versions of the medication to enter the market.
Patent/generic market entry information is not included in the provided label excerpts.
Lipitor is approved by the FDA for the treatment of high cholesterol and cardiovascular disease.
The label excerpt supports indications for lipid disorders and includes “Prevention of Cardiovascular Disease” in clinical studies, but “cardiovascular disease treatment” is broader than the provided Section 1 indication language; without the full label indications wording, the statement is not directly supported by supplied excerpts.
Lipitor has been under review by several regulatory agencies for potential risks associated with muscle damage and liver injury.
No regulatory review history is provided in the supplied label excerpts.
Contradictions
Low
AI Statement
The most common side effects of Lipitor include muscle pain or weakness (rhabdomyolysis).
Label Reference
Section 5.1 — “Rare cases of rhabdomyolysis…” and Section 6 — rhabdomyolysis/myopathy are discussed as serious adverse reactions; Section 6.1 provides “myalgia” as a common discontinuation adverse reaction but does not equate “rhabdomyolysis” with common effects.
Important Omissions
No label-aligned dosing information is provided (e.g., starting dose 10 or 20 mg once daily; dosage range 10–80 mg once daily; timing with/without food).
Importance:
Moderate
No administration or monitoring instructions are mentioned (e.g., liver function tests prior to and at 12 weeks after initiation and after dose increases; periodically thereafter).
Importance:
Moderate
No contraindication/pregnancy and breastfeeding restrictions are addressed despite multiple safety-related claims being made.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response lists multiple adverse effects as “common” and includes serious adverse events (e.g., pancreatitis, anaphylaxis, hypoglycemia/hyperglycemia, lupus/vasculitis) that are not supported by the provided label excerpts, which could mislead expectations about frequency and safety profile. It also incorrectly frames rhabdomyolysis as a common side effect.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple safety/side-effect claims are unsupported or mischaracterize frequency (e.g., rhabdomyolysis as common) and several serious adverse reactions are asserted without support in the provided label excerpts.
Suggested Improvement
Limit safety statements to what the provided label excerpts support (e.g., rare rhabdomyolysis; transaminase elevations incidence and monitoring; use the label’s listed common adverse reactions such as nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, and discontinuation adverse reactions like myalgia/nausea/ALT increase/hepatic enzyme increase). Replace broad indication wording with the label’s Section 1 indication language and include key dosing/monitoring instructions from Section 2 and Section 5.2 where relevant.